CGEN250117C2500
- 0.07
- 0.000.00%
Compugen Newsroom
Compugen Bolsters Cancer Therapy Portfolio With New Patent
Compugen Expands Its Intellectual Property Portfolio With New U.S. Patent Covering Triple Combination Use Of COM902 (Reduced FC Anti-TIGIT) With Anti-PD-1 And Anti-PVRIG Antibodies
Roche Anti-TIGIT Therapy Fails to Extend Survival in Late-stage Lung Cancer Trial
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Truist Financial Maintains Compugen(CGEN.US) With Buy Rating
Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript Summary
Compugen's Financial Surge and Promising Drug Trials
Compugen: Q3 Earnings Snapshot
Earnings Flash (CGEN) COMPUGEN Reports Q3 Revenue $17.1M
Compugen GAAP EPS of $0.01 Misses by $0.05, Revenue of $17.13M Misses by $0.54M
Compugen to Participate in Stifel 2024 Healthcare Conference
Earnings Preview: Compugen to Report Financial Results Pre-market on November 12
$Compugen(CGEN.US)$ is scheduled to release its financial results pre-market on November 12 ET. Earnings PreviewAnalysts estimate $Compugen(CGEN.US)$ to post revenue of USD17.67M for 2024Q3, EPS is
Stifel Maintains Compugen(CGEN.US) With Buy Rating, Maintains Target Price $4
Compugen (CGEN) Receives a Buy From Stifel Nicolaus
Compugen Showcases Promising Data on Ovarian Cancer Therapy
Compugen Strengthens Defence + Security Industry With Strategic Acquisition of SynerSolutions
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Compugen Gears Up to Report Q3 Earnings: Here's What to Expect
Compugen to Present New Clinical Data at SITC 2024
GSK, ITeos Lung Cancer Therapy Outperforms Jemperli in Mid-stage Trial